US5567417A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for inhibiting angiogenesis using heparinase
Assignee: Boston Children's Hospital
•
Filing: 1995-05-01
•
Granted: 1996-10-22
•
Expires: 2015-05-01
Abstract
Abstract Pharmaceutical compositions for delivering an effective dose to a desired site of a heparinase. These compositions are based on the discovery that heparinase alone can inhibit angiogenesis. The effective dosage is dependent not only on the heparinase, but also on the method and means of delivery, which can be localized or systemic. For example, in some applications, as in the treatment of psoriasis or diabetic retinopathy, the inhibitor is delivered in a topical ophthalmic carrier. In other applications, as in the treatment of solid tumors, the inhibitor is delivered by means of a biodegradable, polymeric implant.
Inventors
- 👤 Ramnath Sasisekharan
- 👤 Marsha A. Moses
- 👤 Matthew A. Nugent
- 👤 Charles L. Cooney
- 👤 Robert S. Langer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 08:28
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/88; A; A61; A61P; A61P17/00; A61P27/00; A61P27/02; A61P35/00; A61P9/00; A61K; A61K38/00
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
79 words
A composition inhibiting angiogenesis comprising an effective amount of a heparinase selected from the group consisting of heparinase I and heparinase III from Flavobacterium heparinum in a pharmaceutically acceptable carrier for topical administration to inhibit angiogenesis at a selected site in a non-heparinized patient in need of treatment thereof, wherein the carrier delivers to a site where angiogenesis is to be inhibited between approximately one and four μg heparinase or a concentration of between 10 and 100 nM heparinase.
Claim 2
Dependent Claim
79 words
A composition inhibiting angiogenesis comprising an effective amount of a heparinase selected from the group consisting of heparinase I and heparinase III from Flavobacterium heparinum in a pharmaceutically acceptable carrier for topical administration to inhibit angiogenesis at a selected site in a non-heparinized patient in need of treatment thereof, wherein the carrier delivers to a site where angiogenesis is to be inhibited between approximately one and four μg heparinase or a concentration of between 10 and 100 nM heparinase.
Claim 3
Dependent Claim
14 words
The composition of claim 1 wherein the heparinase is in an acceptable ophthalmic carrier.
Claim 4
Dependent Claim
20 words
The composition of claim 1 wherein the heparinase is in a pharmaceutically acceptable carrier for topical application to the skin.
Claim 5
Dependent Claim
16 words
The composition of claim 1 wherein the heparinase is in a biodegradable, biocompatible polymeric delivery device.
Claim 6
Independent Claim
53 words
A method for inhibiting angiogenesis comprising: administering to a non-heparinized patient in need of treatment thereof to inhibit angiogenesis an effective amount of a heparinase selected from the group consisting of heparinase I and heparinase III from Flavobacterium heparinum in a pharmaceutically acceptable carrier to a site where inhibition of angiogenesis is desired.
Claim 7
Independent Claim
53 words
A method for inhibiting angiogenesis comprising: administering to a non-heparinized patient in need of treatment thereof to inhibit angiogenesis an effective amount of a heparinase selected from the group consisting of heparinase I and heparinase III from Flavobacterium heparinum in a pharmaceutically acceptable carrier to a site where inhibition of angiogenesis is desired.
Claim 8
Dependent Claim
11 words
The method of claim 5 wherein the site is a tumor.
Claim 9
Dependent Claim
19 words
The method of claim 5 further comprising administering the heparinase topically in a pharmaceutical vehicle suitable for topical application.
Claim 10
Dependent Claim
17 words
The method of claim 5 further comprising providing the heparinase in a biodegradable, biocompatible polymeric delivery device.
Claim 11
Dependent Claim
17 words
The method of claim 5 further comprising providing the heparinase in a pharmaceutically acceptable vehicle for injection.
Claim 12
Dependent Claim
21 words
The method of claim 5 further comprising administering the heparinase in a pharmaceutically acceptable vehicle for topical application to the eye.
Claim 13
Dependent Claim
36 words
The method of claim 5 wherein an effective dose at the site where angiogenesis is to be inhibited is between approximately one and four μg heparinase or a concentration of between 10 and 100 nM heparinase.
Claim 14
Dependent Claim
19 words
The method of claim 5 wherein the effective dose is a dose effective in diminishing the symptoms of psoriasis.
Claim 15
Dependent Claim
24 words
The method of claim 5 wherein the effective dose is a dose effective in diminishing the number of blood vessels growing into a tumor.
Claim 16
Dependent Claim
24 words
The method of claim 5 wherein the effective dose is a dose effective in diminishing the symptoms of eye diseases characterized by abnormal neovascularization.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-10-22 | 2000-04-22 | 2000-10-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-10-22 | 2004-04-22 | 2004-10-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-10-22 | 2008-04-22 | 2008-10-22 | $7700.00 | Window Closed / Lapsed |